Last reviewed · How we verify
NCT05554185
Probiotic Supplementation During Pregnancy in Preeclampsia High-risk Groups
NA trial testing aspirin 100mg and probiotics 1 bag in PE (Pre-eclampsia) High-risk Population With Gut Microbiota Dysbiosis During Their Pregnancy in 338 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Nanfang Hospital, Southern Medical University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 338 |
| Start date | 21 September 2022 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2024 |
Drugs / interventions tested
- aspirin 100mg and probiotics 1 bag
Conditions studied
- PE (Pre-eclampsia) High-risk Population With Gut Microbiota Dysbiosis During Their Pregnancy — all drugs for PE (Pre-eclampsia) High-risk Population With Gut Microbiota Dysbiosis During Their Pregnancy →
Sponsor
Nanfang Hospital, Southern Medical University
Who can join
Adults 18 to 50, female only, with PE (Pre-eclampsia) High-risk Population With Gut Microbiota Dysbiosis During Their Pregnancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this randomized controlled study, preventive intervention of aspirin combined with probiotics or aspirin combined with placebo would given to PE (pre-eclampsia) high-risk population with gut microbiota dysbiosis during their pregnancy, and finally assess the efficacy and safety of aspirin combined with probiotics to prevent PE.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
New Ideas for the Prevention and Treatment of Preeclampsia and Their Molecular Inspirations.
Sakowicz A, Bralewska M, Rybak-Krzyszkowska M, Grzesiak M, et al · · 2023 · cited 28× · PMID 37569476 · DOI 10.3390/ijms241512100
Verify or expand the search:
- PubMed search for NCT05554185
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Nanfang Hospital, Southern Medical University trials
Trials by the same sponsor.
- NCT07091994 — A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy · Phase 4 · not yet recruiting
- NCT06444022 — hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation · Phase 1 · withdrawn
- NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
- NCT07481032 — Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients · NA · not yet recruiting
- NCT07511894 — Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05554185 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanfang Hospital, Southern Medical University
- Last refreshed: 26 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05554185.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing